Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
TGFβ inhibitor
DRUG CLASS:
TGFβ inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
M7824 (9)
luspatercept-aamt (4)
BCA101 (3)
CU01 (1)
AMUN-003 (0)
BMS-986416 (0)
BPB-101 (0)
CRB-601 (0)
JS201 (0)
JYB1907 (0)
Oxy210 (0)
PM8001 (0)
SAR439459 (0)
SD 093 (0)
SD 208 (0)
TQB2858 (0)
TQB2868 (0)
sotatercept (0)
ZGGS18 (0)
GT90001 (0)
AGEN1423 (0)
KER-050 (0)
GC 1008 (0)
M7824 (9)
luspatercept-aamt (4)
BCA101 (3)
CU01 (1)
AMUN-003 (0)
BMS-986416 (0)
BPB-101 (0)
CRB-601 (0)
JS201 (0)
JYB1907 (0)
Oxy210 (0)
PM8001 (0)
SAR439459 (0)
SD 093 (0)
SD 208 (0)
TQB2858 (0)
TQB2868 (0)
sotatercept (0)
ZGGS18 (0)
GT90001 (0)
AGEN1423 (0)
KER-050 (0)
GC 1008 (0)
›
Associations
(16)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A1 - Approval
luspatercept-aamt
Sensitive
:
A1
luspatercept-aamt
Sensitive: A1 - Approval
luspatercept-aamt
Sensitive
:
A1
CALR mutation
Myelodysplastic Syndrome
CALR mutation
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
SF3B1 mutation
Myelodysplastic Syndrome
SF3B1 mutation
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
M7824
Sensitive: B - Late Trials
M7824
Sensitive
:
B
M7824
Sensitive: B - Late Trials
M7824
Sensitive
:
B
TMB-H
Non Small Cell Lung Cancer
TMB-H
Non Small Cell Lung Cancer
M7824
Sensitive: B - Late Trials
M7824
Sensitive
:
B
M7824
Sensitive: B - Late Trials
M7824
Sensitive
:
B
PD-L1 expression
Biliary Tract Cancer
PD-L1 expression
Biliary Tract Cancer
M7824
Sensitive: C2 – Inclusion Criteria
M7824
Sensitive
:
C2
M7824
Sensitive: C2 – Inclusion Criteria
M7824
Sensitive
:
C2
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
M7824
Resistant: C3 – Early Trials
M7824
Resistant
:
C3
M7824
Resistant: C3 – Early Trials
M7824
Resistant
:
C3
TGFB1 elevation
Gastroesophageal Cancer
TGFB1 elevation
Gastroesophageal Cancer
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
TGFB1 elevation
Gastric Cancer
TGFB1 elevation
Gastric Cancer
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
IFNG expression
Colorectal Cancer
IFNG expression
Colorectal Cancer
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
IDH2 mutation
Glioblastoma
IDH2 mutation
Glioblastoma
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
M7824
Sensitive: C3 – Early Trials
M7824
Sensitive
:
C3
EGFR amplification
Lung Non-Small Cell Squamous Cancer
EGFR amplification
Lung Non-Small Cell Squamous Cancer
BCA101
Sensitive: C3 – Early Trials
BCA101
Sensitive
:
C3
BCA101
Sensitive: C3 – Early Trials
BCA101
Sensitive
:
C3
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + BCA101
Sensitive: C3 – Early Trials
pembrolizumab + BCA101
Sensitive
:
C3
pembrolizumab + BCA101
Sensitive: C3 – Early Trials
pembrolizumab + BCA101
Sensitive
:
C3
SF3B1 K700E
Myelodysplastic Syndrome
SF3B1 K700E
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: C3 – Early Trials
luspatercept-aamt
Sensitive
:
C3
luspatercept-aamt
Sensitive: C3 – Early Trials
luspatercept-aamt
Sensitive
:
C3
KRAS mutation + PD-L1 expression
Colorectal Cancer
KRAS mutation + PD-L1 expression
Colorectal Cancer
M7824
Sensitive: C4 – Case Studies
M7824
Sensitive
:
C4
M7824
Sensitive: C4 – Case Studies
M7824
Sensitive
:
C4
EGFR expression
Solid Tumor
EGFR expression
Solid Tumor
BCA101
Sensitive: D – Preclinical
BCA101
Sensitive
:
D
BCA101
Sensitive: D – Preclinical
BCA101
Sensitive
:
D
ER positive + ZNF217 overexpression
HER2 Positive Breast Cancer
ER positive + ZNF217 overexpression
HER2 Positive Breast Cancer
Sensitive: D – Preclinical
Sensitive
:
D
Sensitive: D – Preclinical
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login